ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0465

Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women

Suchita Nety1, Xiaosong Wang2, Misti Paudel3, Ying Qi4, Qianru Zhang1, Nancy Shadick5, Michael Weinblatt6, Liya Sisay Getachew7, Gregory McDermott8 and Jeffrey Sparks7, 1Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Natick, MA, 3Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 4Brigham and Women’s Hospital, Boston, 5Brigham & Women's Hospital, Boston, MA, 6Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 7Brigham and Women's Hospital, Boston, MA, 8Brigham and Women's Hospital, Brookline, MA

Meeting: ACR Convergence 2025

Keywords: interstitial lung disease, rheumatoid arthritis, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: RA-associated lung diseases (RA-LD) such as RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR) are more common in men, but risk rises with age for both men and women. However, no studies have examined the role of reproductive factors, such as time since menopause, in RA-LD risk among women.

Methods: We performed a case-control study of reproductive factors and RA-LD risk in women from two established US prospective RA cohorts (an institutional registry and a health care system biobank) who had clinically indicated high-resolution chest computed tomography (CT) imaging. All women had RA by 2010 ACR/EULAR criteria. RA-LD cases were identified using research review of chest CT images by thoracic radiologists and detailed medical record review confirming that participants met criteria for RA-LD. Controls had RA and no evidence of lung disease based on medical record review and were matched to cases by age and RA duration. The index date for cases was the date of RA-LD diagnosis and the index date was assigned to RA-noLD controls. We analyzed women who answered surveys about reproductive health. The primary analysis investigated years since menopause for RA-LD risk. Secondary analyses included age at menarche, pregnancies, ovulatory-years, type of menopause, and age at menopause as well as RA-ILD and RA-BR risk. We used logistic regression to estimate odds ratios for RA-LD, adjusting for chronological age, smoking, and serostatus.

Results: We analyzed 99 RA-LD cases (mean age 65.5 years) and 170 RA-noLD controls (mean age 63.4 years) who answered surveys about female reproductive factors. RA-LD cases had shorter duration of ovulatory-years (mean 33.8 vs. 35.4 years, p=0.037), younger age at menopause (mean 47.0 vs. 48.5 years, p=0.038), and longer time since menopause (mean 18.4 years vs. 14.8 years, p=0.013) than RA-noLD controls (Table 1). In the primary analysis, time since menopause was significantly associated with RA-LD (adjusted OR 1.05 per year, 95%CI 1.004 to 1.10; p=0.034) (Table 2). In the secondary analyses, menarche at age 10 years or younger was associated with higher RA-LD risk than menarche at age 11 to 14 years (adjusted OR 2.54, 95%CI 1.15 to 5.60). Higher ovulatory-years had a trend towards lower RA-LD risk but was not statistically significant after adjustment (OR 0.96 per year, 95%CI 0.92 to 1.003). Younger age at menopause was associated with RA-LD risk (adjusted OR 2.06, 95%CI 1.03 to 4.11 for onset < 45 years vs. 50 to 54 years). There was no association of iatrogenic menopause (surgical, radiation, or chemotherapy) with RA-LD risk. When analyzing RA-ILD and RA-BR separately, results for RA-ILD risk were similar to RA-LD risk (Table 3).

Conclusion: In this first study examining reproductive factors and RA-LD risk in women, longer time since menopause was associated with higher RA-LD risk. Younger ages at menarche and at menopause were each associated with higher RA-LD risk, and results were similar for RA-ILD. Results were not explained by chronological age, RA duration, serostatus, or smoking. These findings suggest that menopausal factors, such as lack of estrogen, may place older women with RA at risk for LD.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Nety: None; X. Wang: None; M. Paudel: None; Y. Qi: None; Q. Zhang: None; N. Shadick: Bristol-Myers Squibb(BMS), 5, Janssen, 5; M. Weinblatt: aclaris, 2, amgen, 2, anaptysbio, 2, Artiva Bio, 2, Biohaven, 2, Bristol-Myers Squibb(BMS), 2, 5, Canfite, 11, Curie Bio, 2, Deep Cure, 2, Eli Lilly, 2, Gilead, 2, Ignite, 2, Inmedix, 11, Janssen, 5, Janux Therapeutics, 2, Johnson and Johnson, 2, Lifordi, 2, Marvel Bio, 2, Matchpoint, 2, Merck/MSD, 2, Neutrolis, 2, Novartis, 2, Sana, 2, Santa Ana, 2, Sci Rhom, 2, scipher medcine corp, 11, SetPoint Medical, 2, Surf Therapeutics, 2, Thymmune, 2, Xencorp, 2, ZuraBio, 2; L. Getachew: None; G. McDermott: None; J. Sparks: Boehringer Ingelheim, 5, Bristol-Myers Squibb (BMS), 5, Janssen, 5.

To cite this abstract in AMA style:

Nety S, Wang X, Paudel M, Qi Y, Zhang Q, Shadick N, Weinblatt M, Getachew L, McDermott G, Sparks J. Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/reproductive-factors-and-risk-of-rheumatoid-arthritis-associated-interstitial-lung-disease-or-bronchiectasis-in-women/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reproductive-factors-and-risk-of-rheumatoid-arthritis-associated-interstitial-lung-disease-or-bronchiectasis-in-women/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology